The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Production of Preclinical Model of REM Sleep Behavior Disorder Using Alpha-synuclein Fibrils
Study Rationale: REM sleep behavior disorder (RBD) is characterized by abnormal motor behaviors during the REM phase of sleep and is highly predictive of Parkinson’s disease (PD). A brain region...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Examining the Action of Potassium Channels and the Inflammasome in a Signaling Axis That Can Serve as a Pharmacological Target Against Parkinson’s Disease
Study Rationale: Both voltage-gated potassium channels and inflammatory signaling are known to be involved in Parkinson’s disease (PD). Each of these signaling systems contributes to the brain...
-
Spring 2022 RFA: Target Advancement Program - Tool Generation, 2022Design and testing of a FRET sensor for Parkin activity
Study Rationale: Parkin is a protein that is encoded by a gene which is frequently mutated in Parkinson’s disease. It is known to be involved in getting rid of damaged mitochondria in cells and this...
-
Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022Project Title: Clinical Development of PDM608, a Potential Neuroprotective and Anti-inflammatory Long-acting Biologic for Parkinson’s Disease
Study Rationale: Targeting neuroinflammation by increasing T regulatory cell numbers is a promising strategy for treating Parkinson’s disease. We propose a Phase 1 trial in non-PD volunteers for our...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Validating BMPs as Novel Drug Candidates for Parkinson’s Disease
Study Rationale: Neurotrophic factors are prime candidates for the development of disease-modifying therapies, based on their properties to restore and maintain the functional integrity of neurons...
-
Parkinson’s Pathway Molecular Data Analysis Program, 2022Evaluating a Microbial Biomarker in Blood Samples for Parkinson’s Disease
Study Rationale: Diagnosing Parkinson’s disease (PD) currently involves evaluation by movement disorder specialists and assessment based on physical examination and questionnaires. This approach is...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.